163 related articles for article (PubMed ID: 29423677)
1. Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan
Chen L; Brown J; Marmaduke DQ; Mayo C; Grau G; Lau YK; Obasaju CK
Support Care Cancer; 2018 Jul; 26(7):2369-2377. PubMed ID: 29423677
[TBL] [Abstract][Full Text] [Related]
2. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Sun W; Li J
Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (EGFR) inhibitor-induced rash: a consecutive patient series that illustrates the need for rigorous palliative trials.
Solomon BM; Jatoi A
J Palliat Med; 2011 Feb; 14(2):153-6. PubMed ID: 21226620
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial.
Amitay-Laish I; Prag-Naveh H; Ollech A; Davidovici B; Leshem YA; Snast I; Popovtzer A; Purim O; Flex D; David M; Brenner B; Ben-Aharon I; Peled N; Hodak E; Stemmer SM
Dermatology; 2021; 237(6):988-994. PubMed ID: 33378750
[TBL] [Abstract][Full Text] [Related]
5. Rash from EGFR inhibitors: opportunities and challenges for palliation.
Solomon BM; Jatoi A
Curr Oncol Rep; 2008 Jul; 10(4):304-8. PubMed ID: 18778556
[TBL] [Abstract][Full Text] [Related]
6. Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial.
Brøndum L; Alsner J; Sørensen BS; Maare C; Johansen J; Primdahl H; Evensen JF; Kristensen CA; Andersen LJ; Overgaard J; Eriksen JG
Acta Oncol; 2018 Sep; 57(9):1159-1164. PubMed ID: 29771169
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
Parmar S; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seeringer A; Paul T; Seufferlein T; Stingl JC
Pharmacogenomics J; 2013 Apr; 13(2):181-8. PubMed ID: 22158333
[TBL] [Abstract][Full Text] [Related]
8. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
9. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
[TBL] [Abstract][Full Text] [Related]
10. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
[TBL] [Abstract][Full Text] [Related]
11. Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer.
Chiang CL; Chen YW; Wu MH; Huang HC; Tsai CM; Chiu CH
J Chin Med Assoc; 2016 May; 79(5):248-55. PubMed ID: 27036494
[TBL] [Abstract][Full Text] [Related]
12. Skin problems and EGFR-tyrosine kinase inhibitor.
Kozuki T
Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
[TBL] [Abstract][Full Text] [Related]
13. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
Hichert V; Scholl C; Steffens M; Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Oncotarget; 2017 May; 8(21):35193-35204. PubMed ID: 28456787
[TBL] [Abstract][Full Text] [Related]
14. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents.
Rhee J; Oishi K; Garey J; Kim E
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S101-6. PubMed ID: 16336749
[TBL] [Abstract][Full Text] [Related]
15. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
Orditura M; De Vita F; Galizia G; Lieto E; Vecchione L; Vitiello F; Martinelli E; Ciardiello F
Oncol Rep; 2009 Apr; 21(4):1023-8. PubMed ID: 19288004
[TBL] [Abstract][Full Text] [Related]
16. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
[TBL] [Abstract][Full Text] [Related]
17. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
Lee Y; Shim HS; Park MS; Kim JH; Ha SJ; Kim SH; Cho BC
Clin Cancer Res; 2012 Mar; 18(6):1760-8. PubMed ID: 22271877
[TBL] [Abstract][Full Text] [Related]
18. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Steffens M; Scholl C; Hichert V; Seufferlein T; Stingl JC
Eur J Cancer; 2014 Jul; 50(11):1855-63. PubMed ID: 24857781
[TBL] [Abstract][Full Text] [Related]
19. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
Schuette W; Schirmacher P; Eberhardt WEE; Dietel M; Zirrgiebel U; Muehlenhoff L; Thomas M
BMC Cancer; 2018 Feb; 18(1):135. PubMed ID: 29402243
[TBL] [Abstract][Full Text] [Related]
20. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash.
Vaubel J; Livingstone E; Schadendorf D; Zimmer L
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1685-9. PubMed ID: 24422792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
